Can pretreatment serum calcium level predict the efficacy of methotrexate in the treatment of severe plaque psoriasis?

  title={Can pretreatment serum calcium level predict the efficacy of methotrexate in the treatment of severe plaque psoriasis?},
  author={Z. Zhai and Lingui Chen and Huan Yang and Jun Yan and Chunyou Wang and Jinxin Yang and Wenying Liu and Zhu Shen},
  journal={Journal of the American Academy of Dermatology},
  volume={73 6},
BACKGROUND The efficacy of methotrexate (MTX) varies in the treatment of psoriasis. OBJECTIVE We sought to identify an indicator from routine pretreatment tests to predict MTX efficacy in the treatment of psoriasis. METHODS In a retrospective analysis of 77 psoriatic patients, the correlation between MTX efficacy and pretreatment routine test results was analyzed with Spearman correlation. The potential risks were further evaluated with a linear regression model. Receiver operating… Expand
Safety and Efficacy of Methotrexate in Psoriasis: A Meta-Analysis of Published Trials
These meta-analyses summarise currently available evidence on MTX in psoriasis and should be of use to gauge whether local results broadly fall within outcomes, and developed an easy to use documentation form to be completed by patients without requirement for additional staff time. Expand
Systemic abnormalities of psoriatic patients: a retrospective study
The systemic condition of psoriatic patients should be observed by clinicians before systemic treatment, and psoriasis patients significantly had higher absolute values of leukocytes and neutrophils, and significantly lower values of lymphocytes. Expand
Poor early response to methotrexate portends inadequate long‐term outcomes in patients with moderate‐to‐severe psoriasis: Evidence from 2 phase 3 clinical trials
The rule indicates that 4 weeks of methotrexate might be sufficient to predict long‐term response with limited safety risk. Expand
Safety and efficacy profile of oral cyclosporine vs oral methotrexate vs oral acitretin in palmoplantar psoriasis: A hospital based prospective investigator blind randomized controlled comparative study
Modified psoriasis area and severity index, Psoriasis severity scale, visual analogue scale, physician global assessment, and PPQOL were used for monitoring response to therapy and improvement in quality of life up to end of study, and thereafter monthly follow-up was done to find duration of remission for next 90 days. Expand
Renal clearance and intracellular half-life essentially determine methotrexate toxicity: A case series
By analyzing 3 cases of myelosuppression during low-dose MTX treatment with mucocutaneous manifestations, it is found that impaired renal elimination to be the leading cause of MTX toxicity and identify the different durations of plasma and intracellular half-lives ofMTX as the main reason for bone marrow suppression in spite of normal MTX trough levels. Expand


Studying the calcium serum level in patients suffering from psoriasis.
It is better to include dairy as calcium resource in daily diet of patients suffering from psoriasis to avoid hypocalcemia, and to include vitamin D and calcium analogues in the treatment of psoriatic patients. Expand
A 52-week trial comparing briakinumab with methotrexate in patients with psoriasis.
Briakinumab showed higher efficacy than methotrexate in patients with moderate-to-severe psoriasis, and serious infections and cancers occurred more frequently with briakinumabs, but the differences were not significant. Expand
Methotrexate versus cyclosporine in moderate-to-severe chronic plaque psoriasis.
A randomized, controlled trial comparing methotrexate and cyclosporine in terms of effectiveness, side effects, and the quality of life for moderate-to-severe chronic plaque psoriasis found no significant differences in efficacy. Expand
Genetic variation in efflux transporters influences outcome to methotrexate therapy in patients with psoriasis.
Data indicate that knowledge of SNPs in genes relevant to methotrexate efflux may be important in selecting patients suitable for this therapy, and single-nucleotide polymorphisms within the efflux transporter genes ABCC1 and ABCG2 are associated with good response to metotrexate therapy in patients with psoriasis. Expand
Advances in the treatment of moderate-to-severe plaque psoriasis.
  • R. Herrier
  • Medicine
  • American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists
  • 2011
Ustekinumab, a new agent that targets IL-12 and IL-23, was approved for marketing in 2009 and offers similar efficacy and safety profiles to the anti-TNF agents. Expand
Calcium channel blockers intake and psoriasis: a case-control study.
A stepwise multivariate logistic regression analysis demonstrated that intake of calcium channel blockers was significantly associated with psoriasis, as compared to the control group (p = 0.018). Expand
Polymorphisms in folate, pyrimidine, and purine metabolism are associated with efficacy and toxicity of methotrexate in psoriasis.
Preliminary evidence is demonstrated that specific polymorphisms of enzymes involved in folate, pyrimidine, and purine metabolism could be useful in predicting clinical response to methotrexate in patients with psoriasis. Expand
Guidelines of care for the management of psoriasis and psoriatic arthritis: section 4. Guidelines of care for the management and treatment of psoriasis with traditional systemic agents.
The efficacy and safety, and recommendations for the use of the 3 most commonly used, and approved, traditional systemic agents: methotrexate, cyclosporine, and acitretin are discussed. Expand
Methotrexate in dermatology
This review of methotrexate's pharmacokinetics, mode of administration, dosing guidelines, side effect profile, and medication interactions will offer practical guidelines for dose initiation and adjustment, and summarize new research on its mechanism of action and implications for future therapy. Expand
Outcomes of methotrexate therapy for psoriasis and relationship to genetic polymorphisms
This work has shown that genetic variation across the methotrexate metabolic pathway might enable prediction of both efficacy and toxicity of the drug. Expand